Consolidated Statement Of Cash Flows

Daito Pharmaceutical Co., Ltd. - Filing #7310181

Concept 2023-06-01 to
2024-05-31
As at
2024-05-31
As at
2023-05-31
2022-06-01 to
2023-05-31
As at
2022-05-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
6,265,000,000 JPY
6,514,000,000 JPY
Interest and dividends received
66,000,000 JPY
58,000,000 JPY
Income taxes paid
-1,265,000,000 JPY
-2,411,000,000 JPY
Interest paid
-40,000,000 JPY
-13,000,000 JPY
Net cash provided by (used in) operating activities
5,182,000,000 JPY
4,155,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,220,000,000 JPY
-5,505,000,000 JPY
Net cash provided by (used in) investing activities
-5,930,000,000 JPY
-5,566,000,000 JPY
Proceeds from sale of investment securities
335,000,000 JPY
JPY
Other, net
10,000,000 JPY
-8,000,000 JPY
Cash flows from financing activities
Purchase of treasury shares
-1,176,000,000 JPY
-110,000,000 JPY
Dividends paid
-907,000,000 JPY
-931,000,000 JPY
Proceeds from long-term borrowings
4,000,000,000 JPY
3,000,000,000 JPY
Repayments of long-term borrowings
-2,029,000,000 JPY
-1,638,000,000 JPY
Net cash provided by (used in) financing activities
-183,000,000 JPY
616,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
51,000,000 JPY
20,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-879,000,000 JPY
-774,000,000 JPY
Cash and cash equivalents
2,727,000,000 JPY
3,607,000,000 JPY
4,381,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.